CYP2C19*2 polymorphism and clopidogrel resistance

Joob, Beuy; Wiwanitkit, Viroj; Joob, Beuy; Wiwanitkit, Viroj

doi:10.24875/acm.20000396

Servicios Personalizados

Revista

Articulo

Indicadores

Citado por SciELO
Accesos

Links relacionados

Similares en SciELO

Otros
Otros

Permalink

Archivos de cardiología de México

versión On-line ISSN 1665-1731versión impresa ISSN 1405-9940

Arch. Cardiol. Méx. vol.90 no.4 Ciudad de México oct./dic. 2020 Epub 10-Feb-2021

https://doi.org/10.24875/acm.20000396

Carta al editor

CYP2C19*2 polymorphism and clopidogrel resistance

CYP2C19*2 polimorfismo y resistencia a clopidogrel

Beuy Joob¹^*

Viroj Wiwanitkit²

^¹Sanitation Medical Academic Center, Bangkok, Thailand

^²Department of Tropical Medicine, Hainan Medical University, Hainan, China

Dear Editor,

We read the publication on the “Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico” with a great interest¹. Cedillo-Salazar et al. noted that “the presence of the CYP2C19*2 allele is related to resistance to the antiplatelet effect of CLO”¹. Indeed, the CYP2C19*2 polymorphism can result in molecular change, and this can further result in alteration of phenotypic expression. However, there are also other genetic factors that might relate to clopidogrel resistance. The examples of genetic polymorphisms that might relate to clopidogrel resistance are CES1 gene and MDR1 polymorphisms²,³. Further, a study that addresses the effect of other possible confounding genetic polymorphisms is recommended.

References

1. Cedillo-Salazar FR, Martínez-Jacobo L, Pérez-Páramo YX, Cerda-Flores R, Martínez LE, Jaime-Pérez JC, et al. Association of CYP2C19*2 polymorphism with clopidogrel resistance among patients with high cardiovascular risk in Northeastern Mexico. Arch Cardiol Mex. 2019;89:324-9. [ Links ]

2. Mirzaev KB, Osipova DV, Kitaeva EJ, Shprakh VV, Abdullaev SP, Andreev DA, et al. Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. Drug Metab Pers Ther. 2019;1-8. [ Links ]

3. Al-Husein BA, Al-Azzam SI, Alzoubi KH, Khabour OF, Nusair MB, Alzayadeen S. Investigating the effect of demographics, clinical characteristics, and polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on clopidogrel resistance. J Cardiovasc Pharmacol. 2018;72:296-302. [ Links ]

FundingThe present investigation has not received any specific scholarship from the public, commercial, or non-profit agencies.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Received: December 16, 2019; Accepted: June 01, 2020

^* Correspondence: Beuy Joob E-mail: beuyjoob@hotmail.com

^{Conflicts of interest}

None.

Instituto Nacional de Cardiología Ignacio Chávez. Published by Permanyer. This is an open ccess article under the CC BY-NC-ND license